SCHEMBL16014358

SCHEMBL16014358

COc1ccc(Cn2ncc(C(N)=O)c2N)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.71
NPC1 O15118 1/20 0.56
LMNA P02545 1/20 0.56
ALDH1A1 P00352 1/20 0.51
NPBWR1 P48145 5/20 0.50
PDE8B O95263 1/20 0.50
ALOX15 P16050 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PTPN1 P18031 1/20 0.48
MCHR1 Q99705 1/20 0.46
UCHL1 P09936 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 2/20 0.44
MAPT P10636 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
RAF1 P04049 2/20 0.44
CCNB2 O95067 1/20 0.44
CCNE2 O96020 1/20 0.44
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29049972 0.89 PTPN1 (0.60) TSHRNPC1LMNAALDH1A1NPBWR1
SCHEMBL370942 0.85 LMNA (0.80) TSHRNPC1LMNAALDH1A1UCHL1
SCHEMBL28327863 0.82 NPBWR1 (0.50) TSHRNPC1LMNANPBWR1PDE8B
SCHEMBL174541 0.81 TSHR (0.76) TSHRNPC1LMNAALDH1A1MAPT
Hydrochloric Acid SCHEMBL4102414 0.80 NPBWR1 (0.52) TSHRNPBWR1PDE8BALOX15L3MBTL1
SCHEMBL1801455 0.80 NPBWR1 (0.54) TSHRNPC1LMNAALDH1A1NPBWR1
SCHEMBL30050755 0.79 PDE8B (0.46) TSHRNPC1NPBWR1PDE8BALOX15
SCHEMBL1491119 0.79 TSHR (0.67) TSHRNPC1LMNAALDH1A1NPBWR1
SCHEMBL16014600 0.78 TSHR (0.44) TSHRALDH1A1NPBWR1PDE8BALOX15
Sulfuric Acid SCHEMBL2923461 0.78 NPBWR1 (0.50) TSHRNPC1LMNANPBWR1PDE8B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105143220-B Pyrazole derivatives 豪夫迈·罗氏有限公司 2018-06-22 CN disclosed
US-9694012-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2017-07-04 US disclosed
US-9694012-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2017-07-04 US disclosed
US-9694012-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2017-07-04 US disclosed
EP-2964646-B1 NOVEL PYRAZOL DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-04-19 EP disclosed
EP-2964646-B1 NOVEL PYRAZOL DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-04-19 EP disclosed
US-20170035769-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-09 US disclosed
US-20170035769-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-09 US disclosed
US-20170035769-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-09 US disclosed
US-9512132-B2 Pyrazole compounds as CB2 agonists HOFFMANN-LA ROCHE INC. (US) 2016-12-06 US disclosed
US-9512132-B2 Pyrazole compounds as CB2 agonists HOFFMANN-LA ROCHE INC. (US) 2016-12-06 US disclosed
US-9512132-B2 Pyrazole compounds as CB2 agonists HOFFMANN-LA ROCHE INC. (US) 2016-12-06 US disclosed
US-20160083391-A1 TRICYCLIC PIPERAZINE DERIVATIVE SUNOVION PHARMACEUTICALS INC (US) 2016-03-24 US disclosed
EP-2964646-A1 NOVEL PYRAZOL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-01-13 EP disclosed
US-20150376192-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-31 US disclosed
US-20150376192-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-31 US disclosed
US-20150376192-A1 NOVEL PYRAZOL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-31 US disclosed
WO-2014135507-A1 NOVEL PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed
WO-2014135507-A1 NOVEL PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376192-A1 NOVEL PYRAZOL DERIVATIVES CYP3A43, ADRB3, UGT1A3 TSHR 1771/4885NPC1 406/4885LMNA 2981/4885
US-20160083391-A1 TRICYCLIC PIPERAZINE DERIVATIVE PDE3A, PDE5A, PDE2A TSHR 3962/4885NPC1 2829/4885LMNA 2962/4885
US-20170035769-A1 NOVEL PYRAZOL DERIVATIVES CYP3A43, ADRB3, UGT1A3 TSHR 1771/4885NPC1 406/4885LMNA 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.